Michael J. Farrell - May 16, 2022 Form 4 Insider Report for RESMED INC (RMD)

Role
Chief Executive Officer
Signature
Michael J. Farrell, Chief Executive Officer
Stock symbol
RMD
Transactions as of
May 16, 2022
Transactions value $
-$787,957
Form type
4
Date filed
5/17/2022, 01:20 PM
Previous filing
May 17, 2022
Next filing
Jun 16, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RMD ResMed Common Stock Options Exercise $328K +5.68K +1.4% $57.76 411K May 16, 2022 Direct F1
transaction RMD ResMed Common Stock Sale -$1.12M -5.68K -1.38% $196.61 405K May 16, 2022 Direct F1, F2, F3
holding RMD ResMed Common Stock 3.88K May 16, 2022 Lisette and Michael Farrell Foundation
holding RMD ResMed Common Stock 5.09K May 16, 2022 Lisette and Michael Farrell Family Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RMD ResMed Common Stock Options Options Exercise $0 -5.68K -5.1% $0.00 106K May 16, 2022 ResMed Common Stock 5.68K $57.76 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transaction was conducted under a Rule 10b5-1 plan.
F2 This transaction was executed in multiple trades at prices ranging from $195.10 to $198.04. The price reported above reflects the weighted average sale price.
F3 Includes 30.8872 shares of ResMed stock purchased on April 29, 2022, through the ResMed Employee Stock Purchase Plan.
F4 Represents date options first became exercisable. Options vest 1/3 per year.